Dr Ruth Ladenstein talks to ecancer about data she presented at ASCO 2025 from the HR-NBL1/SIOPEN trial.

In this large international trial involving 705 children with high-risk neuroblastoma, researchers compared long-term infusion (LTI) versus short-term infusion (STI) of dinutuximab beta (DB) following standard intensive therapy. Over a median follow-up of 7.7 years, LTI was associated with significantly better outcomes, including higher 5-year event-free survival (65% vs. 56%) and lower relapse rates (33% vs. 42%) compared to STI.

Multivariable analysis confirmed LTI as an independent predictor of improved survival. These results build on previous findings that LTI reduces treatment-related side effects, suggesting that it offers both enhanced efficacy and safety for this vulnerable patient population.